Matthew Diamond, DO
Nephrology · Augusta, GANPI 1760410351
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $9,037 of the $14,409 with a category attached, or 62.7%. 33 manufacturers reported payments, led by Calliditas Therapeutics US Inc. at 24.2% of the total. Reporting peaked in 2024 at $5,031 and has fallen 67.5% since, to $1,636 in 2025. Among nephrology clinicians in GA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 444 payments — averaging $32.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Calliditas Therapeutics US Inc.$3K
- GSK$2K
- AstraZeneca$1K
- Amgen$1K
- Vifor Pharma, Inc.$665
- Bayer$644
- plus $5K from 27 others
Across 151 payments — averaging $6077.92 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$563K
- Quanta Dialysis Technologies Inc$200K
- Bayer$90K
- Novo Nordisk AS$66K
What the payments were for
- Consulting fees$4,63832%
- Travel & lodging$2402%
- Food & beverage$9,03763%
- Education$2962%
- Entertainment$1991%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Calliditas Therapeutics US Inc. | 27 | $3,488 |
| GSK | 18 | $2,061 |
| AstraZeneca(2 entities) | 62 | $1,077 |
| Amgen(2 entities) | 48 | $1,076 |
| Vifor Pharma, Inc. | 40 | $665 |
| Bayer | 34 | $644 |
| Novartis | 17 | $632 |
| Eli Lilly | 14 | $630 |
| Otsuka America Pharmaceutical, Inc. | 23 | $533 |
| Mallinckrodt Hospital Products Inc. | 21 | $499 |
| Aurinia Pharma U.S., Inc. | 26 | $450 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $345 |
| Fresenius USA Marketing, Inc. | 21 | $340 |
| OPKO Pharmaceuticals, LLC | 19 | $336 |
| Novo Nordisk | 4 | $262 |
| Quanta Dialysis Technologies Inc | 2 | $231 |
| Akebia Therapeutics Inc | 8 | $181 |
| Travere Therapeutics, Inc. | 14 | $155 |
| Astrazeneca UK Limited | 1 | $135 |
| Daiichi Sankyo Inc. | 7 | $127 |
| Lilly USA, LLC | 5 | $112 |
| Boehringer Ingelheim | 3 | $65 |
| ANI Pharmaceuticals, Inc. | 2 | $53 |
| Ardelyx, Inc. | 3 | $51 |
| Mallinckrodt Enterprises LLC | 4 | $49 |
| Medline Industries LP | 1 | $46 |
| Xeris Pharmaceuticals, Inc. | 2 | $44 |
| Ultragenyx Pharmaceutical Inc. | 2 | $36 |
| Apellis Pharmaceuticals, Inc. | 1 | $27 |
| Merck | 1 | $20 |
| Astellas Pharma US Inc | 1 | $18 |
| Boston Scientific | 1 | $12 |
| Shire North American Group Inc | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,409 in reported general payments places this provider in the 90th percentile of 388 nephrology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VelphoroSucroferric Oxyhydroxide | 19 | $52,707 |
| JardianceEmpagliflozin | 34 | $38,802 |
| LokelmaSodium Zirconium Cyclosilicate | 15 | $22,512 |
| KerendiaFinerenone | 23 | $20,708 |
| FarxigaDapagliflozin Propanediol | 18 | $16,344 |
| Eplerenone | 19 | $3,530 |
| Torsemide | 48 | $1,658 |
| Bumetanide | 57 | $1,511 |
| Chlorthalidone | 87 | $1,458 |
| Nifedipine ErNifedipine | 49 | $1,404 |
| Sevelamer Carbonate | 31 | $1,296 |
| Calcium Acetate | 24 | $1,242 |
| Furosemide | 243 | $1,110 |
| Losartan Potassium | 131 | $1,069 |
| Amlodipine Besylate | 145 | $946 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Fresenius USA Marketing, Inc.Velphoro | $340 | $52,70719 claims |
| AstraZenecaLokelma, Farxiga | $1,077 | $38,85733 claims |
| Boehringer IngelheimJardiance | $65 | $38,80234 claims |
| BayerKerendia | $644 | $20,70823 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 388 nephrology providers in Georgia.
Other nephrology in Augusta
- Don WilliamsonAugusta$104K
- Barton BrezinaAugusta$47K
- Laura MulloyAugusta$11K
- Syed BabarAugusta$8K
- Muralidharan JagadeesanAugusta$8K
- Shameem BeighAugusta$7K
- Harold HubertAugusta$7K
- Devesh PatelAugusta$6K
- Sagar PanseMacon$542K
- Sheldon ShoreAtlanta$474K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.